SparingVision raises €44.5m for retinitis pigmentosa gene th...

French biotech SparingVision has raised 44.5 million euros ($52.7 million) to develop its gene therapy for a rare ocular disease.

Takeda to make $200m loss after Novartis' dry-eye drug hits ...

Novartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing it to make a loss of $200 million this quarter. 

Bausch + Lomb buys US rights to Stada's Lucentis biosimilar

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent protecte

UK court imposes safety rules on off-label use of Avastin in...

Bayer has said a new UK court ruling could limit off-label use of Roche's Avastin in ophthalmology by imposing stricter safety and consent measures.

First patient dosed in trial of Allergan/Editas’ CRISPR blin...

Novartis' Beovu safety woes could cost billions of dollars, ...

The launch of Novartis’ Beovu ophthalmology drug could be compromised after a safety warning from doctors over several cases of sight-threatening inflammation of blood vessels.